Stock Price & Analysis

Based on current trends and analysis, INCY stock is showing resilience with a moderate buy consensus and upcoming catalysts, making it a hold. The stock has potential upside driven by its pipeline and strong commercial execution.

Price Prediction for INCY Stock in 2025

The price target for Incyte (INCY) stock in 2025 is expected to reach $85.00, driven by strong pipeline growth and positive Phase 3 trial results for Opzelura. Analysts maintain a Moderate Buy consensus with an average price target of $77.50, supported by the company's diversified portfolio and upcoming catalysts.

The S1 support level for INCY Stock is $67.01 ,The R1 resistant level for INCY Stock is $72.42.

As of the end of day on 2025-03-14, the price of INCY Stock was $69.03.

The target price for INCY Stock according to analyst rating is 77.50, with the highest price target at 100.00 and the lowest at 52.00. Analysts have a Moderate Buy rating on INCY Stock overall.

The market cap of INCY is $13.1B.

Analysis and Insights

Valuation Metrics

Incyte's current valuation metrics suggest a mixed outlook. The stock's price-to-earnings (P/E) ratio is elevated compared to industry peers, indicating potential overvaluation. However, the company's revenue growth and pipeline strength justify some premium.

Financial Performance

Incyte reported strong quarterly revenue of $1.18 billion, up from $1.01 billion year-over-year, with a net profit of $201.21 million. This growth reflects solid commercial execution, particularly from key franchises like Jakafi and Opzelura.

Analyst Sentiment

Analysts are divided on Incyte. While Citi and Stifel have raised their price targets, citing strong commercial performance and pipeline potential, others like RBC Capital have lowered targets due to concerns over Opzelura's guidance and upcoming pivotal trial results for povorcitinib.

Recent News and Pipeline Updates

Incyte's Phase 3 TRuE-PN1 trial for Opzelura showed promise, but the companion TRuE-PN2 trial failed to meet statistical significance due to a high placebo response. This introduces uncertainty about the drug's future growth prospects.

Insider Sentiment

Insider sentiment is negative, with 77 insiders selling shares recently, including a notable sale by EVP Sheila A. Denton. This could indicate internal concerns about near-term growth.

Conclusion

Incyte is fairly valued given its growth prospects and pipeline potential, but risks like clinical trial outcomes and increasing competition could impact its upside. While not significantly overvalued, investors should monitor upcoming catalysts closely.

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.

Incyte Corporation (INCY) is expected to reach a stock price of $88 to $100 by 2030, driven by strong revenue growth from key products like Jakafi and Opzelura, as well as promising clinical trials. Analysts maintain a Moderate Buy consensus with an average price target of $77.50, reflecting confidence in the company's pipeline and growth potential. However, risks include insider selling activity and potential trial setbacks.

INCY has a total of 2524 employees.